Clinical Trial Update: Study of ONO-4538 in Gastric Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of nivolumab (ONO-4538) for gastric cancer has completed. No results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer | Phase 2, Phase 3 | Status: COMPLETED